Results 131 to 140 of about 21,002 (186)

Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics. [PDF]

Front Pharmacol
Alqahtani S.
europepmc   +1 more source

Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real world cohort. [PDF]

Int J Hematol
Schweneker K, Lenk M, Kern W, Haferlach C, Meggendorfer M, Pohlkamp C, Haferlach T.   +6 more
europepmc   +1 more source

Synthetic peptide analogs derived from bcr/abl fusion proteins induce heteroclitic human T cell responses.

Haematologica, 2006
openaire   +2 more sources

Allosteric PROTACs: Expanding the Horizon of Targeted Protein Degradation. [PDF]

J Am Chem Soc
Frost A, O'Connor S, Ciulli A.
europepmc   +1 more source

Rare Atypical Ela3 BCR-ABL transcript in acute Lymphoblastic Leukemia: a case report. [PDF]

Afr Health Sci
Xu L, Han T, Wei S, Wang N.
europepmc   +1 more source

The silent players: Atypical <i>BCR‑ABL </i>isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review). [PDF]

Oncol Rep
Zhou X, Li A, Kong D, Shi Y, Zhang P, Shan N.   +5 more
europepmc   +1 more source

Unveiling Cryptic <i>BCR-ABL1</i> Rearrangements: Diagnostic Challenges and Clinical Impact in Myeloid Malignancies. [PDF]

Int J Mol Sci
Ferrari A, Salvesi C, Fonzi E, Giannini B, Tonelli M, Zacheo I, Paganelli M, Lo Schiavo F, Rosetti M, Simonetti G, Marconi G.   +10 more
europepmc   +1 more source

Concurrent NPM1::CCDC28A and BCR::ABL1 fusions in extramedullary blast crisis of chronic myeloid leukemia: A case report and literature review. [PDF]

Ann Hematol
Zhu L, Yi K, Zhou J, Hu G, He J, Lan H, Chen M, Sun L, Zheng B, Li R.   +9 more
europepmc   +1 more source

Real-World Outcomes With Low-Dose Dasatinib (50 mg) in Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety. [PDF]

Cancer Rep (Hoboken)
Gangadaran N, Mamlekar H, Saha S, Kashyap R, Yadav S, Rahman K, Gupta R, Vijayaran M, Singh M, Chandra D.   +9 more
europepmc   +1 more source

Efficacy of larotrectinib in pediatric cancers with <i>NTRK</i> gene fusions. [PDF]

Transl Pediatr
Houghton PJ, Bjornsti MA.
europepmc   +1 more source